Opexa Therapeutics

📍 The Woodlands, United States👥 23 employees💰 Last funded Mar 2014
Biotechnology Research🌐 opexatherapeutics.com
Website LinkedIn
Opexa Therapeutics, Inc. (NASDAQ:OPXA) is a publicly traded biotechnology company dedicated to the development of personalized immunotherapies with the potential to treat major illnesses, including multiple sclerosis as well as other autoimmune diseases, such as neuromyelitis optica. These therapies are based on Opexa's proprietary T-cell technology. The Company’s leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive Multiple Sclerosis. Top-line results from the Abili-T trial are expected in early 4th quarter of 2016. Opexa’s mission is to lead the field of Precision Immunotherapy® by aligning the interests of patients, employees and shareholders.
2
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Opexa Therapeutics?
Opexa Therapeutics has 2 investors on record on gritt.io.
When did Opexa Therapeutics last raise funding?
The most recent investment in Opexa Therapeutics recorded on gritt.io was in March 2014.
What industry is Opexa Therapeutics in?
Opexa Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Opexa Therapeutics based?
Opexa Therapeutics is headquartered in The Woodlands, United States.